ANI Pharmaceuticals, Inc. (ANIP)
ANIP Price and Sentiment
ANIP Latest news
7 Overbought Stocks to Be Very Careful of Right Now
2021-10-01 13:10While the market rally this year has been incredible, worrying developments suggest investors should watch out for overbought stocks. The post 7 Overbought Stocks to Be Very Careful of Right Now appeared first on InvestorPlace.
ANI Pharmaceuticals to Present at Cantor Virtual Global Healthcare Conference 2021
2021-09-20 16:30BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Cantor Virtual Global Healthcare Conference 2021 as follows: Date: Thursday, September 30, 2021 Time: 8:00 a.m. ET Webcast Link: https://wsw.com/webcast/cantor12/anip/2073680 The presentation will be webcast live at the aforementioned time, and archived for 30 days ther
ANI Pharmaceuticals Announces Launch of Nebivolol Tablets
2021-09-17 06:50BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the launch of Nebivolol Tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg. ANI's Nebivolol Tablets is the generic version of the reference listed drug (“RLD”) Bystolic®. The current annual U.S. market for Bystolic 2.5 mg, 5 mg, 10 mg, and 20 mg strengths is approximately $1.05 billion, according to IQVIA/IMS Health, a leading healthcare data and analytics provider. "The launch of Nebivolol
ANI Pharma's Purified Cortrophin Gel Application Under FDA Review
2021-08-31 09:57The FDA has accepted ANI Pharmaceuticals Inc's (NASDAQ: ANIP) supplemental marketing application for Purified Cortrophin Gel. The application seeks approval for multiple indications, including multiple sclerosis, rheumatoid arthritis, and nephrotic syndrome.
ANI Pharmaceuticals Announces FDA Acceptance of Purified Cortrophin® Gel Supplemental New Drug Application for Multiple Indications Including Multiple Sclerosis, Rheumatoid Arthritis, and Nephrotic Syndrome
2021-08-31 06:50BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq:ANIP) today announced that the Company's supplemental New Drug Application (“sNDA”) for Purified Cortrophin® Gel (“Cortrophin Gel”) has been accepted by the U.S. Food and Drug Administration (“FDA”) for review. “FDA's acceptance of our sNDA for Cortrophin Gel marks a significant milestone for ANI. With a PDUFA target action date of October 29, 2021, we are one step closer to bringing a much-needed produ
ANI Pharmaceuticals' (ANIP) CEO Nikhil Lalwani on Q2 2021 Results - Earnings Call Transcript
2021-08-06 12:20ANI Pharmaceuticals' (ANIP) CEO Nikhil Lalwani on Q2 2021 Results - Earnings Call Transcript
ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Surpass Estimates
2021-08-06 09:59ANI (ANIP) delivered earnings and revenue surprises of 3.08% and 1.73%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
ANI Pharmaceuticals Reports Second Quarter 2021 Results
2021-08-06 07:24BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced business highlights and financial results for the three and six months ended June 30, 2021. Second Quarter and Recent Business Highlights: The Company refiled its supplemental new drug application (“sNDA”) for Cortrophin® Gel with the U.S. Food and Drug Administration (“FDA” or the “Agency”) on June 29, 2021; goal date is October 29, 2021; Acquisition of Novitium Pharma LLC (“Novi
Analysts Estimate ANI Pharmaceuticals (ANIP) to Report a Decline in Earnings: What to Look Out for
2021-07-30 16:43ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ANI Pharmaceuticals to Discuss Second Quarter 2021 Financial Results on August 6, 2021
2021-07-22 16:30BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2021 financial results on Friday, August 6, 2021. Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows: Date Friday, August 6, 2021 Time 8:30 a.m. ET Toll free (U.S.) 866-342-8591 Webcast